Only very limited patients in the triple combo currently, never the less very encouraging data,
efficacy from 10 patients. Early efficacy signals from 10 of 14 patients show ORR of 70% and Disease Control Rate (DCR) of 90% (according to RECIST 1.1), of course noting the very small patient subset evaluated (n=10). It is encouraging at this early stage only 1 of 10 patients have progressive disease.
Only very limited patients in the triple combo currently, never...
-
- There are more pages in this discussion • 1,696 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $548.3M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 38.3¢ | 37.0¢ | $577.8K | 1.537M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 209884 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 116701 | 37 |
View Market Depth
| Last trade - 12.53pm 23/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |